Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Cochrane database of systematic reviews (Online)

Volumn 7, Issue , 2012, Pages

  Wagner, Anna Dorothea ^a   Thomssen, Christoph ^b   Haerting, Johannes ^b   Unverzagt, Susanne ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; FEMALE; HUMAN; META ANALYSIS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866450288     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: None     Document Type: Review

References (0)